Table 2.
Associations between analgesic use and ovarian cancer risk in the Ovarian Cancer Cohort Consortium (n = 758 829)
| Analgesic use | No. of events (cases) | Person-years | HR* (95% CI) | P† |
|---|---|---|---|---|
| Aspirin | ||||
| Infrequent/nonuse | 2404 | 4 946 886 | 1.00 (ref) | |
| Frequent use‡ | 851 | 1 408 656 | 0.95 (0.88 to 1.03) | .23 |
| Frequent use by duration vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1402 | 3 150 285 | 1.00 (ref) | |
| Frequent/0.5–<5 y | 239 | 504 116 | 0.92 (0.80 to 1.06) | .24 |
| Frequent/5–<10 y | 93 | 171 582 | 0.90 (0.72 to 1.12) | .33 |
| Frequent/10+ y | 212 | 305 987 | 1.15 (0.98 to 1.34) | .09 |
| Categories of frequent use vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1936 | 3 245 903 | 1.00 (ref) | |
| <Daily use | 156 | 161 238 | 1.06 (0.90 to 1.26) | .49 |
| Daily use§ | 449 | 545 499 | 0.90 (0.82 to 1.00) | .05 |
| Categories of frequent use by duration vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1402 | 3 150 285 | 1.00 (ref) | |
| <Daily/0.5–<5 y | 152 | 379 640 | 1.02 (0.85 to 1.21) | .87 |
| <Daily/5–<10 y | 43 | 108 355 | 0.92 (0.67 to 1.26) | .60 |
| <Daily/10+ y | 113 | 260 503 | 1.12 (0.92 to 1.37) | .26 |
| Daily/0.5–<5 y | 87 | 124 476 | 0.79 (0.63 to 0.99) | .04 |
| Daily/5–10 y | 50 | 63 227 | 0.88 (0.65 to 1.18) | .39 |
| Daily/10+ y | 99 | 45 484 | 1.18 (0.93 to 1.50) | .18 |
| Frequent use by dose vs infrequent/nonuse | ||||
| Infrequent/nonuse | 392 | 436 742 | 1.00 (ref) | |
| Frequent low dose | 115 | 72 719 | 0.99 (0.79 to 1.23) | .91 |
| Frequent normal dose | 144 | 130 684 | 0.94 (0.77 to 1.15) | .55 |
| Nonaspirin NSAID | ||||
| Infrequent/nonuse | 2305 | 3 798 980 | 1.00 (ref) | |
| Frequent use‡ | 426 | 614 745 | 1.00 (0.90 to 1.11) | .96 |
| Frequent use by duration vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1168 | 2 051 666 | 1.00 (ref) | |
| Frequent/0.5–<5 y | 122 | 237 614 | 0.94 (0.78 to 1.14) | .54 |
| Frequent/5–<10 y | 64 | 75 230 | 1.10 (0.85 to 1.42) | .49 |
| Frequent/10+ y | 36 | 29 429 | 1.19 (0.84 to 1.68) | .33 |
| Categories of frequent use vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1982 | 3 049 045 | 1.00 (ref) | |
| <Daily use | 104 | 124 937 | 1.07 (0.88 to 1.31) | .50 |
| Daily use§ | 237 | 319 625 | 0.97 (0.84 to 1.11) | .65 |
| Categories of frequent use vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1168 | 2 051 666 | 1.00 (ref) | |
| <Daily/0.5–<5 y | 83 | 159 749 | 1.02 (0.81 to 1.28) | .88 |
| <Daily/5–<10 y | 39 | 43 940 | 1.31 (0.95 to 1.81) | .10 |
| <Daily/10+ y | 15 | 18 356 | 1.10 (0.66 to 1.84) | .72 |
| Daily/0.5–<5 y | 39 | 77 865 | 0.81 (0.58 to 1.14) | .23 |
| Daily/5–<10 y | 25 | 31 290 | 0.86 (0.57 to 1.30) | .48 |
| Daily/10+ y | 21 | 11 074 | 1.27 (0.80 to 2.01) | .32 |
| Acetaminophen | ||||
| Infrequent/nonuse | 1421 | 2 583 452 | 1.00 (ref) | |
| Frequent use‡ | 152 | 213 668 | 1.05 (0.88 to 1.24) | .61 |
| Frequent use by duration vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1386 | 2 425 711 | 1.00 (ref) | |
| Frequent/0.5–<5 y | 61 | 95 060 | 0.99 (0.76 to 1.29) | .93 |
| Frequent/5–<10 y | 50 | 50 683 | 1.16 (0.87 to 1.54) | .32 |
| Frequent/10+ y | 37 | 51 266 | 1.01 (0.73 to 1.41) | .96 |
| Categories of frequent use vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1179 | 2 120 248 | 1.00 (ref) | |
| <Daily use | 35 | 43 645 | 0.99 (0.70 to 1.39) | .94 |
| Daily use§ | 71 | 62 759 | 1.28 (1.00 to 1.65) | .05 |
| Categories of frequent use by duration vs infrequent/nonuse | ||||
| Infrequent/nonuse | 1386 | 2 425 711 | 1.00 (ref) | |
| <Daily/0.5–<5 y | 33 | 69 923 | 0.87 (0.62 to 1.22) | .42 |
| <Daily/5–<10 y | 25 | 35 311 | 0.98 (0.66 to 1.46) | .93 |
| <Daily/10+ y | 22 | 39 950 | 0.89 (0.58 to 1.36) | .58 |
| Daily/0.5–<5 y | 28 | 25 137 | 1.21 (0.81 to 1.81) | .35 |
| Daily/5–<10 y | 25 | 15 372 | 1.42 (0.94 to 2.13) | .09 |
| Daily/10+ y | 15 | 11 315 | 1.24 (0.75 to 2.08) | .40 |
Hazard ratios and 95% confidence intervals were estimated from Cox proportional hazards models stratified by study cohort and adjusted for baseline age (continuous), body mass index (<20, 20–24.9, 25–29.9, 30–34.9, ≥35 kg/m2), number of births (none, one, two, three, four or more full–term births), duration of oral contraceptive (OC) use (never, ≤1, >1–5, >5–10, >10 years), and duration of menopausal hormone therapy use (premenopausal, never, ≤5, >5–10, >10 years). CI = confidence interval; HR = hazard ratio; NSAID = nonsteroidal anti-inflammatory drug.
P value was calculated using a two-sided Wald test.
Frequent: use at least ∼4–5 days/wk for 6 months or longer.
Daily: use at least ∼6–7 days/wk or ≥28 days per month for 6 months or longer.